Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BlueRock Therapeutics

www.bluerocktx.com

Latest From BlueRock Therapeutics

BlueRock Therapeutics: Sizing Up The Regenerative Power Of Cells

Bayer's novel 2016 joint venture with the venture capital group Versant Ventures has spawned something like a big pharma, new science start-up, with an open mandate to disrupt drug development through generous endowments in the scarce commodities of freedom, time and patience.

C-Suite Speaks Innovation

Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration

Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.

Deals Business Strategies

Bayer Bosses Beg Risk-Averse Europe To Rethink

The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

Regenerative Medicine Innovation

J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies

Companies working on cell and gene therapies and novel approaches to neurological diseases participated in a roundtable discussion during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.

Regenerative Medicine Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • BlueRock Therapeutics
  • Senior Management
  • Emile Nuwaysir, PhD, Pres. & CEO
    Shane Kovacs, CBO & CFO
    Robert Deans, PhD, CTO
    Michael Scott, PhD, SVP, Product Dev.
    Derek Hei, PhD, SVP, Manufacturing, Quality & Reg.
    Joachim Fruebis, PhD, Chief Dev. Officer
  • Contact Info
  • BlueRock Therapeutics
    One Broadway
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register